State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis: 2025 Update on Emerging Therapeutics


State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis: 2025 Update on Emerging Therapeutics Banner

Add to Calendar State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis: 2025 Update on Emerging Therapeutics 10/26/2025 9:00:00 AM 10/26/2025 4:00:00 PM America/New_York For More Details: https://mskcc.cloud-cme.com/course/courseoverview?EID=56029 Description: This one-day symposium offers a state-of-the-art update in benign hematology, with a special emphasis on emerging therapeutics. Now in its 10th year, the 2025 program will focus on:Complex management scenarios in hemostasis and thrombosis, including stroke in cancer, cardiac thrombosis, and thrombotic risk in acute lymphoblastic leukemia (ALL)Advances in management of hemolytic anemias, with a focus on... Zuckerman Research Center, 417 East 68th Street false MM/DD/YYYY


Date & Location
Sunday, October 26, 2025, 9:00 AM - 4:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY

Specialties
Specialties - Emergency Medicine, Hematology, Hematopathology, Hospitalist, Immunotherapy, Internal Medicine, Interventional Radiology, Leukemia, Nurse Practitioner, Oncology and Hematology, Physician Assistant, Pulmonary Medicine, Transfusion Medicine

Overview

This one-day symposium offers a state-of-the-art update in benign hematology, with a special emphasis on emerging therapeutics. Now in its 10th year, the 2025 program will focus on:

  • Complex management scenarios in hemostasis and thrombosis, including stroke in cancer, cardiac thrombosis, and thrombotic risk in acute lymphoblastic leukemia (ALL)

  • Advances in management of hemolytic anemias, with a focus on the therapeutic management of hereditary anemia, paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease, and other complement-mediated hemolytic disorders

  • Hematologic complications related to cellular therapies and immunotherapies

The program will address complex thrombosis management scenarios—including stroke in cancer, cardiac thrombosis, and thrombotic risk in acute lymphoblastic leukemia (ALL)—as well as emerging therapies such as factor XI inhibitors and anticomplement agents, and the unique challenges associated with their use. Ample time will be provided for Q&A and discussion with the faculty.

The target audience for this symposium includes general medicine, hematology/oncology, fellows, hospitalists, nocturnists, emergency medicine providers, advanced practice providers and other healthcare professionals who manage and treat thrombotic and bleeding disorders. Please note that this symposium will be offered exclusively in person; a virtual attendance option will not be available.

Following the symposium, registrants will receive access to an online syllabus featuring select PDF slides from faculty presentations and recorded session videos.


Objectives
At the conclusion of this symposium, attendees will be able to:

  1. Discuss current updates in the management of challenging benign hematologic conditions, with a focus on emerging therapeutics
  2. Analyze current data and discuss emerging FXI inhibitors
  3. Describe anticomplement therapies
  4. Recognize the challenges in diagnosis and management of hematologic complications of immunotherapy

Registration

Included in registration, attendees will be offered continental breakfast, lunch, and refreshment breaks. Please contact [email protected] at least one week prior to the course if you have any special dietary requests or require any specific accommodations for joining us onsite.

Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information.

Registration Rates

  • Physicians (MDs, PhDs, and DOs): $300

  • Advanced Practice Providers: $250

  • Nursing and Other Healthcare Professionals: $200

  • Residents, Fellows, and Students: $100(non-refundable)

  • Industry Professionals*: $525

  • MSK Employees: Complimentary

  • Patients, Advocates, and Caregivers: Complimentary; Requests can be submitted here.

*An “industry professional” is defined as any individual, regardless of their profession type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company. View our Registration Policy for Industry Professionals for more information.

For details on our cancellation terms, please review our Cancellation Policy.


Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 6.50 Medical Knowledge MOC Points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification Assessment Recognition program; and

  • 6.50 Lifelong Learning (CME) credit towards the American Board of Pathology’s (ABPath) Continuing Certification program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABPath MOC/CC credit.

ANCC CNE Statement

An application has been submitted for ANCC CNE contact hours.